Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents

Avranas, Konstantinos; Imprialos, Κonstantinos; Stavropoulos, Konstantinos; Lales, Georgios; Manafis, Alexandos; Skalkou, Anastasia; Kihm, Lars

doi:10.2174/1871529x18666180206160838

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cells cannot efficiently absorb sugar because they do not interact with insulin normally [11,12]. Additionally, the pancreas might be incapable of regulating blood sugar levels due to low insulin production [13]. The liver promotes gluconeogenesis and exaggeration of cytokine release in the digestive system (Fig 1).…”

Section: Etiopathology Of Type 2 Diabetesmentioning

confidence: 99%

Insilico designing of novel imidazothiadiazole derivatives as SGLT2 inhibitors in emerging potential for Antidiabetic Therapeutics

Mehra

2023

Preprint

View full text Add to dashboard Cite

Background. Deficiency of insulin signaling in type 2 diabetes results from insulin resistance or defective insulin secretion and induce hyperglycemia. By reducing glycated hemoglobin, SGLT2 inhibitors improve hyperuricemia, blood lipids and weight loss without increasing the risk of hypoglycemia. By targeting this pathway, SGT2 inhibitors can become a prominent target in the management of type 2 diabetes. Objective. Interpretation of molecular docking and physicochemical properties of imidazo (2,1-b)-1,3,4 thiadiazole scaffold as SGLT2 inhibitors. Methods. The chemical structures of 108 molecules were drawn by using Chemdraw professional 15.0. Further, their energy minimization was also carried out by using Chem Bio Draw three-dimensional (3D) Ultra 12.0. Molecular docking was also carried out using a Molegro Virtual Docker to identify the best-fitting molecules and to identify the potential leads on the basis of dock score. The predicted parameters of drug-likeness according to Lipinski’s rule of five, such as molecular weight, log P, hydrogen bond acceptor, hydrogen bond donors, and number of rotatable bonds of the selected compounds, were predicted using pKCSM software. Results. 108 molecules were designed by employing different substitutions on imidazo-thiadiazole nucleus as SGLT2 inhibitors. Out of these 10 compounds were found to have better interactions with the active site of SGLT2 protein and the highest dock scores as compared to that of canagliflozin. Compounds 39a and 39b demonstrated good interactions and the highest dock score of -155.428 and -142.786 respectively. The insilicophysicochemical properties of the best compounds had also been determined. Additionally, these compounds suggested a good pharmacokinetic profile as per Lipinski's rule of five (orally active drugs). Conclusion. The imidazo (2,1-b)-1,3,4 thiadiazole scaffold was employed to design a novel SGLT2 inhibitor that exhibits maximum binding interactions with essential amino acids as well orally active.

show abstract

Section: Etiopathology Of Type 2 Diabetesmentioning

confidence: 99%

Insilico designing of novel imidazothiadiazole derivatives as SGLT2 inhibitors in emerging potential for Antidiabetic Therapeutics

Mehra

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor developed for the treatment of adults with T2DM (5). Canagliflozin promotes urinary glucose excretion, resulting in decreased plasma glucose, a mild osmotic diuresis and a net caloric loss (6, 7).…”

Section: Introductionmentioning

confidence: 99%

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

Wang

et al. 2018

J Pharm Pharm Sci

View full text Add to dashboard Cite

Our results indicated that canagliflozin may have a protective effect on fatty liver in T2DM patients. The limitation was that the liver biopsy was hard to obtain in published studies. More RCTs specified on NAFLD are needed to get further information. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

show abstract

Multiflorumisides H K, stilbene glucosides isolated from Polygonum multiflorum and their in vitro PTP1B inhibitory activities

Yang

Tian

et al. 2020

Fitoterapia

View full text Add to dashboard Cite

Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents

Cited by 6 publications

References 0 publications

Insilico designing of novel imidazothiadiazole derivatives as SGLT2 inhibitors in emerging potential for Antidiabetic Therapeutics

Insilico designing of novel imidazothiadiazole derivatives as SGLT2 inhibitors in emerging potential for Antidiabetic Therapeutics

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

Multiflorumisides H K, stilbene glucosides isolated from Polygonum multiflorum and their in vitro PTP1B inhibitory activities

Contact Info

Product

Resources

About